No Data
No Data
Zhongheng Group (600252.SH): The subsidiary plans to cooperate with Hongyi Group to establish a healthcare equity investment fund
Gelonghui, May 21丨Zhongheng Group (600252.SH) announced that in order to achieve Zhongheng Group's endogenous and epitaxial two-wheel drive development, promote Zhongheng Group to become a leading pharmaceutical company for clinical solutions in the cardiovascular field and a comprehensive benchmark enterprise in the medical and health industry, accelerate mergers and acquisitions and improve capital operation efficiency. Zhongheng Yixin, a wholly-owned subsidiary of Zhongheng Group, plans to establish a healthcare equity investment fund with Hongyi Group. The investment direction is mainly mid-stage biomedical projects, including innovative medical devices, accurate diagnosis, digital medicine, etc. The total amount raised by this fund is 70
Zhongheng Group (600252.SH): Total share repurchase capital to be adjusted to 200 million yuan to 300 million yuan
Gelonghui Group (600252.SH) announced on May 21丨Zhongheng Group () announced that the total capital to repurchase shares will be adjusted from “not less than RMB 150,000 (inclusive) and no more than RMB 200,000 (inclusive)” to “not less than RMB 200,000 (inclusive) and no more than RMB 300,000 (inclusive)”. The use of share buybacks was changed from “to implement equity incentives” to “to implement equity incentives or employee stock ownership plans.”
Zhongheng Group (600252.SH): A total of 12.103 million shares have been repurchased
Gelonghui Group (600252.SH) announced on May 7, 2024, that as of April 30, 2024, the company had repurchased 12,103,000 shares of the company through centralized bidding transactions, accounting for 0.35% of the company's total share capital of 3,451,489,454 shares. The highest price of the repurchase transaction was 2.44 yuan/share, the lowest price was 2.20 yuan/share, and the total amount of capital paid was RMB 27,023,304.00 (excluding transaction fees such as stamp duty and transaction fees).
Why Investors Shouldn't Be Surprised By Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) Low P/S
With a price-to-sales (or "P/S") ratio of 2.6x Guangxi Wuzhou Zhongheng Group Co.,Ltd (SHSE:600252) may be sending bullish signals at the moment, given that almost half of all the Pharmaceuticals comp
Zhongheng Group (600252.SH): Net profit of 54.711,200 yuan in the first quarter
Gelonghui, April 29丨Zhonghui Group (600252.SH) released its report for the first quarter of 2024, achieving operating income of 806 million yuan, an increase of 20.34% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of RMB 26.0875 million, an increase of 1461.09% over the previous year; net profit attributable to shareholders of listed companies was 54.7112 million yuan, with basic earnings per share of 0.016 yuan.
Zhongheng Group (600252.SH): Initial repurchase of 0.21% of shares
Gelonghui Group (600252.SH) announced on April 16, 2024, that on April 16, 2024, the company repurchased 7,168,600 shares of the company's shares for the first time through centralized bidding transactions, accounting for 0.21% of the company's total share capital of 3,451,489,454 shares. The highest price of the repurchase transaction was 2.25 yuan/share, the lowest price was 2.20 yuan/share, and the total amount of capital paid was RMB 15,959,328.00 (excluding transaction fees such as stamp duty and transaction fees).
No Data